Zolinza (vorinostat)

We investigated the effect of the HDACi suberoylanilide hydroxamic acid (SAHA) on cell viability and immunogenic cell death (ICD), as well as its combinatory potential with a SOCS3 peptidomimetic (KIRCONG chim PEG), designed to inhibit STAT3 phosphorylation (pSTAT3), in TNBC cell lines...Conditioned media from co-treated MDA-MB-231 cells promoted CD4+T cell activation, as shown by increased HLA-DR and CD69 expression. Overall, these findings indicate that SOCS3 functional replacement enhances SAHA anti-cancer and immunogenic effects in IL-6 high TNBC cells, supporting a context-dependent combinatory strategy targeting the IL-6/STAT3 axis.

P1, N=83, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Apr 2027

P1/2, N=35, Recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Jun 2026 --> Jun 2035 | Trial primary completion date: Jun 2026 --> Jun 2035

These findings establish MPERSRGs as key determinants of tumor-immune interactions and provide actionable biomarkers for risk stratification and precision therapy selection in cancer.

Eukaryotic transcriptome sequencing revealed that the combination treatment primarily inhibits tumor cell proliferation by modulating TRKC protein expression and suppressing phosphorylation of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway. Therefore, our results indicate that nobiletin, a natural BH3 mimetic, synergizes with vorinostat to regulate both apoptosis and autophagy in NSCLC.

P2, N=282, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027

In our opinion, they are worth applying in the development of HDACs inhibitors. Overall, this study provides a new structure design for HDACs inhibitors and also offers promising novel HDACs inhibitors with potential antiproliferative activity against several types of cancers.

P1/2, N=83, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027

Drug sensitivity analysis demonstrated that high TYMS expression positively correlated with sensitivity to Afatinib and Gefitinib, but negatively correlated with Methotrexate and Vorinostat. In conclusion, TYMS is upregulated in LUAD and may serve as an independent prognostic biomarker and therapeutic target.

P1, N=20, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Apr 2027

P1, N=30, Recruiting, New York Medical College | Trial completion date: Dec 2024 --> Dec 2027 | Trial primary completion date: Dec 2023 --> Dec 2026

Although pancreatic ductal adenocarcinoma (PDAC) is generally considered an immunologically "cold" tumor, approximately 20% of cases can be classified as immune-hot. Single-cell RNA sequencing revealed that the Gemcitabine-SAHA combination remodels the tumor microenvironment by enhancing CD8+ T cell function and depleting cancer-associated fibroblasts. Clinically, we defined a CD8high/FASNhigh/PARP9high signature that identifies an IE patient subgroup with poor survival, representing those most likely to benefit from the "Gemcitabine-Nivolumab-SAHA" triple-combination therapy.